Precision BioSciences Inc. Stock News

Systems Oncology is using AI to Innovate Drug Discovery & Development and is being honored with a 2020 AZBio Fast Lane Award for their achievements.

Qihan Biotech published research reporting the successful production of its first clinical xenotransplantation prototype.

DURHAM, Caroline du Nord, et PARIS, 17 sept. 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq : DTIL), une société biotechnologique en phase...

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced t

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced t

Wrapbook which powers payroll, insurance, and compliance for the entertainment industry today announces $3.6M in Seed funding for its software platfor

DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® ge

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -5.00% and -80.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q2 results.Quarterly Results Earnings per share decreased 61.54% year over year to ($0.63), which missed the est

Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma PBCAR0191 and PBCAR20A Clinical Studies Progressing; Updated Interim Dat

Deputi bidang Meteorologi Badan Meteorologi Klimatologi dan Geofisika (BMKG) Guswanto mengatakan fenomena awan hitam memanjang yang terjadi di Meulaboh ...

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced t

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced f